Management of Urothelial Carcinoma: Strategies for Addressing Health Disparities and Promoting Equitable Care

Access Activity

Overview / Abstract:

Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.

Program Overview
The treatment landscape has evolved significantly for patients with advanced/metastatic urothelial carcinoma. With new evidence and indications for immunotherapy and other targeted therapies, oncology clinicians are challenged to stay abreast of updated practice guidelines, clinical data for new therapies, and strategies for monitoring and mitigating adverse events. In this activity, expert faculty will review novel therapeutic approaches for advanced/metastatic urothelial carcinoma and current evidence to support individualized treatment decisions. Strategies for optimizing patient outcomes and improving multidisciplinary coordinated care for patients with advanced/metastatic urothelial carcinoma will also be discussed.

This enduring activity is a recorded session from Oncology Congress that took place on September 24, 2022.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Evaluate ways to improve multidisciplinary, coordinated care and communication for patients with urothelial carcinoma from rural and underserved settings
Integrate current clinical evidence and guideline recommendations into treatment plans with new and emerging targeted therapies for patients with advanced/metastatic urothelial carcinoma
Apply best practice strategies to monitor and manage adverse events associated with advanced/metastatic urothelial carcinoma therapy

Expiration

Dec 15, 2023

Discipline(s)

Nursing CNE, Physician CME

Format

Online

Credits / Hours

1.0 AMA PRA Category 1 Credit

Accreditation

ACCME

Presenters / Authors / Faculty

Faculty
FACULTY_NAME
Matthew D. Galsky, MD
Professor of Medicine
Icahn School of Medicine at Mount Sinai
Director, Genitourinary Medical Oncology
Mount Sinai Hospital
New York, NY

FACULTY_NAME
Sucharu (Chris) Prakash, MD
Oncologist & Regional Medical Director
Texas Oncology - Paris
Paris, TX

Sponsors / Supporters / Grant Providers

Astellas and Seagen; and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.

Keywords / Search Terms

Relias LLC Relias LLC., FreeCME., Urothelial Carcinoma Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map